enGene Holdings Inc. $ENGN Stock Position Lowered by Blue Owl Capital Holdings LP

Key Points

• Blue Owl Capital cut its stake in enGene by 12.1% in Q3, selling 450,000 shares and leaving it with 3,278,106 shares (about 6.40% of enGene, $22.39M), which represents 6.9% of Blue Owl’s portfolio and is its third-largest holding.
• Analysts have grown more positive — upgrades include Raymond James to Strong Buy ($27 PT), Morgan Stanley to overweight ($19), Oppenheimer ($33) and Jefferies initiating coverage at Buy ($28) — the consensus rating is a Moderate Buy with an average price target of $23.29.
• enGene is a clinical-stage biopharma with a $581.5M market cap and a 52-week range of $2.65–$12.25; it reported a quarterly loss of $0.73 per share (missed estimates) and analysts expect about -1.56 EPS for the fiscal year, with roughly 64% institutional ownership.

Blue Owl Capital Holdings LP cut its holdings in enGene Holdings Inc. (NASDAQ:ENGN - Free Report) by 12.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 3,278,106 shares of the company's stock after selling 450,000 shares during the period. enGene accounts for 6.9% of Blue Owl Capital Holdings LP's investment portfolio, making the stock its 3rd biggest position. Blue Owl Capital Holdings LP owned approximately 6.40% of enGene worth $22,389,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of ENGN. Cresset Asset Management LLC bought a new stake in enGene during the 2nd quarter valued at $36,000. Paloma Partners Management Co bought a new position in shares of enGene in the second quarter worth $38,000. PFS Partners LLC purchased a new position in shares of enGene in the third quarter valued at $61,000. Finally, Affinity Asset Advisors LLC bought a new stake in shares of enGene during the 2nd quarter valued at $280,000. 64.16% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on ENGN shares. Raymond James Financial raised enGene from an "outperform" rating to a "strong-buy" rating and set a $27.00 price objective on the stock in a report on Tuesday, November 11th. Morgan Stanley upped their price target on enGene from $18.00 to $19.00 and gave the company an "overweight" rating in a research report on Wednesday, November 12th. Oppenheimer reissued an "outperform" rating and issued a $33.00 price target (up from $30.00) on shares of enGene in a report on Wednesday, November 12th. Citigroup restated a "market outperform" rating on shares of enGene in a research report on Monday, January 5th. Finally, Jefferies Financial Group assumed coverage on shares of enGene in a research note on Friday, January 30th. They set a "buy" rating and a $28.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $23.29.

enGene Price Performance

NASDAQ:ENGN opened at $8.68 on Friday. enGene Holdings Inc. has a 52-week low of $2.65 and a 52-week high of $12.25. The stock has a fifty day moving average of $9.58 and a 200 day moving average of $8.01. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.30 and a current ratio of 6.30. The firm has a market capitalization of $581.47 million, a price-to-earnings ratio of -3.79 and a beta of -0.29.

enGene (NASDAQ:ENGN - Get Free Report) last announced its earnings results on Monday, December 22nd. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.18). On average, research analysts expect that enGene Holdings Inc. will post -1.56 EPS for the current fiscal year.

enGene Profile

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.

Want to see what other hedge funds are holding ENGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for enGene Holdings Inc. (NASDAQ:ENGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.